middl
east
respiratori
syndrom
coronaviru
merscov
focu
intern
attent
sinc
identif
epidemiolog
character
sporad
commun
case
amplifi
hospitalbas
outbreak
healthcar
facil
countri
contin
experienc
import
case
signific
outbreak
involv
case
korea
mortal
intern
guidanc
clinic
manag
yet
develop
facil
healthcar
provid
outsid
middl
east
receiv
patient
littl
experi
clinic
manag
mer
case
occur
like
littl
time
critic
apprais
literatur
put
pharmacolog
option
identifi
publish
literatur
manag
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
search
pubm
us
cdc
websit
april
total
public
retriev
critic
apprais
publish
literatur
therapeut
mer
vitro
experi
anim
studi
case
report
current
treatment
option
mer
categor
immunotherapi
virusspecif
antibodi
convalesc
plasma
polyclon
monoclon
antibodi
produc
vitro
genet
modifi
anim
antivir
agent
use
therapeut
merscov
remain
investig
therapeut
agent
potenti
benefit
warrant
investig
includ
convalesc
plasma
interferonbribavirin
combin
therapi
lopinavir
corticosteroid
ribavirin
monotherapi
mycophenol
acid
like
toxic
exceed
potenti
benefit
middl
east
respiratori
syndrom
coronaviru
merscov
first
isol
patient
kingdom
saudi
arabia
june
approxim
incid
case
date
manag
middl
east
howev
diseas
export
countri
north
america
asia
europ
africa
major
solitari
case
caus
secondari
spread
june
korea
experienc
largest
outbreak
outsid
saudi
arabia
extend
chain
transmiss
involv
multipl
gener
case
includ
patient
death
demonstr
potenti
merscov
widespread
humantohuman
transmiss
lead
disrupt
health
socioeconom
system
anticoronaviru
therapi
challeng
develop
coronavirus
biolog
divers
rapidli
mutat
henc
effect
agent
one
strain
especi
target
replic
mechan
may
useless
anoth
strain
anim
studi
logist
technic
difficult
number
anim
model
avail
limit
found
design
biosafeti
level
laboratori
fundament
differ
sarscov
merscov
put
question
basi
appli
evid
treatment
former
latter
although
merscov
phylogenet
relat
sarscov
differ
biolog
makeup
pathogenesi
clinic
manifest
contrast
sarscov
bind
angiotensinconvert
enzym
receptor
merscov
bind
receptor
dipeptidyl
peptidas
merscov
vivo
target
wide
varieti
cell
includ
type
ii
alveolar
cell
noncili
epitheli
cell
clara
cell
endotheli
cell
ciliat
epitheli
cell
infect
sarscov
merscov
unlik
sarscov
also
infect
replic
human
monocytederiv
macrophag
increas
express
major
histocompat
complex
class
costimulatori
molecul
lead
exagger
activ
immun
respons
includ
express
interferong
chemokin
differ
receptor
usag
suscept
type
type
iii
interferon
may
account
differ
diseas
pattern
organ
tropism
viru
shed
current
treatment
option
mer
categor
immunotherapi
virusspecif
antibodi
convalesc
plasma
polyclon
monoclon
antibodi
produc
vitro
genet
modifi
anim
antivir
agent
attempt
also
made
repurpos
approv
pharmaceut
drug
merscov
treatment
multipl
compound
includ
oestrogen
receptor
dopamin
receptor
antagonist
display
activ
merscov
sarscov
vero
cell
model
consider
data
avail
welldesign
clinic
trial
yet
complet
low
case
number
one
site
known
difficulti
trial
outbreak
set
refer
public
review
identifi
search
pubm
us
cdc
websit
april
search
term
use
combin
treatment
middl
east
respiratori
syndrom
coronaviru
respiratori
ill
middl
east
respiratori
syndrom
coronaviru
addit
refer
list
articl
also
consid
type
studi
includ
vitro
vivo
clinic
studi
treatment
option
merscov
extrapol
sarscov
relev
articl
treatment
two
coronavirus
review
full
text
identifi
studi
retriev
articl
publish
foreign
languag
chines
one
author
nativ
speaker
total
articl
critic
assess
merscov
sarscov
featur
therapeut
includ
convalesc
plasma
immunoglobulin
monoclon
antibodi
ribavirin
proteas
inhibitor
interferon
corticosteroid
nitazoxanid
immunomodulatori
agent
includ
cyclosporin
chloroquin
mycophenol
acid
fusion
inhibitor
convalesc
plasma
use
clinic
sinc
treat
infecti
diseas
convalesc
serum
use
recent
sar
ebola
outbreak
trial
undertaken
inadequ
term
defin
safeti
efficaci
treatment
diseas
deem
convalesc
plasma
promis
nearterm
therapi
mer
whointern
sever
acut
respiratori
emerg
infect
consortium
merscov
outbreak
readi
workshop
howev
due
lack
clinic
trial
posit
paper
publish
march
state
clinic
use
convalesc
plasma
regard
investig
merscov
prophylact
therapeut
treatment
hightitr
mer
immun
camel
serum
abl
diminish
weight
loss
reduc
lung
histolog
chang
acceler
viru
clearanc
merscov
mice
convalesc
plasma
sar
patient
shown
via
indirect
immunofluoresc
test
contain
crossreact
antibodi
bcoronavirus
includ
merscov
howev
neutral
crossreact
sarscov
merscov
demonstr
crossreact
sera
therefor
unlik
use
therapeuticallyan
import
consider
mer
affect
countri
sar
survivor
china
canada
singapor
novel
merscovspecif
polyand
monoclon
antibodi
mab
develop
rapidli
produc
immun
anim
antibodi
human
phage
librari
memori
b
cell
recov
patient
transchromosom
cattl
success
gener
purifi
human
igg
rapidli
decreas
viral
lung
titr
receptortransduc
mice
monoclon
antibodi
target
merscov
spike
glycoprotein
shown
strong
neutral
effect
vitro
anim
studi
protein
surfac
structur
protein
critic
viru
entri
host
cell
mous
model
transnas
mab
effect
prophylact
postexposur
set
viral
clearanc
similarli
rhesu
model
mab
administr
result
reduc
lung
patholog
computedtomographi
evalu
howev
caveat
use
mab
potenti
viral
escap
resist
emerg
safeti
profil
vivo
effect
need
explor
two
case
report
use
intraven
immunoglobulin
ivig
treat
mer
one
patient
saudi
arabia
given
ivig
togeth
highdos
corticosteroid
thrombocytopenia
mer
case
import
usa
ivig
given
day
ill
patient
recov
ivig
unlik
effect
due
expect
absenc
merscov
antibodi
usa
research
protocol
collect
test
convalesc
plasma
recov
mer
patient
formul
share
saudi
arabia
initi
feasibl
safeti
studi
may
protocol
promot
clinic
character
mer
patient
screen
recov
expos
individu
complet
expect
june
howev
studi
hamper
logist
challeng
local
technic
capac
donor
suppli
recent
commun
princip
investig
studi
reveal
antibodi
titr
convalesc
plasma
low
produc
therapeut
effect
random
control
studi
rct
util
convalesc
plasma
sar
outbreak
one
retrospect
four
prospect
studi
sarsaffect
patient
undertaken
china
hong
kong
taiwan
demonstr
earlier
discharg
rapid
decreas
viraemia
surviv
benefit
promis
outcom
also
observ
delay
administr
pentaglobin
igmenrich
immunoglobulin
prepar
led
improv
clinic
paramet
radiolog
appear
sever
sar
patient
continu
deterior
despit
corticosteroid
ribavirin
therapi
similarli
subsequ
outbreak
prospect
cohort
studi
intens
care
patient
show
use
convalesc
plasma
abl
reduc
respiratori
tract
viral
load
serum
cytokin
respons
mortal
posit
effect
patient
confirm
multicentr
rct
use
hyperimmun
ivig
intens
care
patient
earli
administr
within
day
symptom
onset
review
jac
associ
lower
viral
load
reduc
mortal
systemat
review
metaanalysi
univers
nottingham
includ
studi
sarscov
infect
sever
influenza
conclud
statist
signific
reduct
mortal
convalesc
plasma
administ
earli
compar
placebo
therapi
howev
studi
deem
low
qualiti
heterogen
lack
control
group
effect
convalesc
plasma
ivig
could
discern
effect
patient
comorbid
stage
ill
treatment
possibl
theoret
drawback
convalesc
plasma
immunopotenti
infect
passiv
immun
effect
specif
limit
number
virus
includ
coronavirus
sever
hepat
report
immun
ferret
thought
mediat
antibodi
enhanc
sarscov
infect
liver
howev
reproduc
monkey
model
model
sarscov
proteinspecif
igg
level
monkey
lung
tissu
found
increas
rechalleng
sarscov
enhanc
viral
replic
immunopotenti
clinic
use
convalesc
plasma
immun
globulinrel
product
treatment
coronaviru
report
plasma
product
vari
region
depend
diseas
epidemiolog
may
contain
therapeut
level
antibodi
public
health
england
evalu
uk
ivig
show
merscov
neutral
activ
saudi
arabia
seroposit
antimerscov
found
amongst
healthi
volunt
vari
provinc
age
exposur
camel
interferon
coronavirus
shown
suppress
interferon
ifn
respons
host
subdu
ifn
respons
diminish
antigen
present
reduc
antivir
adapt
immun
respons
therefor
recombin
ifn
ifn
induc
especi
type
ii
identifi
treatment
modal
mer
abil
augment
host
respons
type
b
type
ii
g
type
iii
l
ifn
exhibit
activ
sarscov
ifnb
potent
compar
ifna
g
merscov
time
sensit
ifna
sarscov
vero
cell
virus
caus
lysi
target
cell
effect
inhibit
ifn
uninfect
cell
ifn
highest
util
prophylaxi
earli
postexposur
ifn
display
synergist
characterist
use
combin
vitro
studi
administ
togeth
ifnb
ifng
inhibit
sarscov
plaqu
format
replic
combin
ribavirin
effect
reduc
merscov
replic
vero
cell
combin
decreas
dose
ribavirin
requir
respect
biolog
plausibl
combin
studi
via
microarray
show
ribavirin
ifna
target
merscov
gene
involv
pathogen
recognit
cytokin
releas
immun
respons
combin
found
effect
rhesu
macaqu
common
marmoset
model
ifn
ribavirin
andor
lopinavir
administ
treatment
led
reduc
viru
replic
moder
host
respons
improv
clinic
outcom
clinic
data
ifn
corticosteroid
studi
openlabel
uncontrol
studi
patient
diagnos
probabl
sar
interferon
corticosteroid
arm
better
oxygen
satur
rapid
resolut
radiograph
lung
abnorm
lower
level
creatin
kinas
compar
corticosteroid
arm
howev
standard
regimen
use
advers
event
well
document
merscov
role
ifna
highlight
studi
compar
earli
immun
respons
two
patient
first
patient
succumb
rapidli
found
significantli
lower
ifna
secret
serum
bronchoscopi
lavag
sampl
patient
surviv
infect
use
ribavirin
describ
four
case
report
five
retrospect
cohort
studi
studi
involv
mainli
critic
ill
patient
requir
mechan
ventil
mortal
five
retrospect
studi
rang
higher
recogn
mortal
associ
mer
intern
studi
method
heterogen
time
ifn
ribavirin
combin
treatment
administ
inconsist
describ
one
studi
investig
impact
earlier
administr
ifn
ribavirin
studi
involv
mechan
ventil
patient
twentytwo
given
ribavirin
median
time
therapi
administr
day
compar
receiv
ribavirin
treatment
group
improv
surviv
day
mortal
treatment
group
versu
compar
group
day
mortal
treatment
group
versu
compar
group
anoth
retrospect
studi
show
signific
differ
outcom
patient
given
combin
ribavirin
mortal
patient
receiv
compar
receiv
effect
ifnb
mycophenol
acid
combin
therapi
studi
recent
retrospect
observ
studi
saudi
arabia
involv
patient
although
univari
analysi
demonstr
improv
surviv
patient
treat
combin
multivari
analysi
consid
sever
ill
show
associ
treatment
surviv
ifn
wellestablish
agent
routin
avail
use
viral
hepat
malign
leukaemia
renal
cell
carcinoma
multipl
sclerosi
shorteract
prepar
prefer
rather
pegylatedifn
achiev
fast
onset
action
util
suggest
better
earli
infect
inhal
ifnb
remain
investig
phase
trial
patient
asthma
proteas
inhibitor
wellestablish
antivir
favour
toxic
profil
use
treatment
hiv
proteas
inhibitor
prevent
viral
replic
bind
enzym
respons
review
proteolyt
cleavag
lopinavir
one
hiv
proteas
inhibitor
repurpos
sar
mer
treatment
previous
shown
block
sarscov
main
proteas
pro
vitro
anim
studi
lopinavir
found
inhibitori
merscov
vitro
vero
cell
mean
effect
concentr
ec
mm
screen
fdaapprov
drug
antimerscov
activ
lopinavir
plasma
concentr
similar
observ
patient
hiv
atazanavir
ritonavir
found
inact
screen
common
marmoset
model
lopinavirritonavir
effect
bring
improv
clinic
radiolog
patholog
find
lung
tissu
lower
mean
viral
load
lung
kidney
tissu
compar
untreat
anim
observ
studi
patient
affect
sar
suggest
reduct
mortal
less
progress
acut
respiratori
distress
syndrom
ard
lopinavirritonavir
combin
ribavirin
patient
receiv
ribavirin
lopinavirritonavir
corticosteroid
lower
day
ard
mortal
receiv
ribavirin
corticosteroid
howev
studi
determin
systemat
review
inconclus
due
select
treatment
bias
two
case
report
greec
korea
show
posit
outcom
lopinavir
ritonavir
type
ifn
ribavirin
combin
therapi
greek
patient
clear
viraemia
day
initi
tripl
therapi
administ
day
ill
ribavirin
broad
spectrum
activ
viral
infect
sarscov
four
six
vitro
studi
found
antivir
effect
howev
virolog
effect
ribavarin
found
sarscov
anim
model
use
monotherapi
mous
model
even
show
ribavirin
may
prolong
enhanc
viral
replic
lung
similarli
merscov
ribavirin
inhibitori
high
concentr
vero
cell
inhibitori
concentr
ic
ribavirin
determin
mgml
howev
human
level
mgml
achiev
follow
high
mg
intraven
dose
ribavirin
monotherapi
studi
anim
model
merscov
systemat
review
sar
treatment
studi
deem
inconclus
due
inconsist
report
outcom
inconsist
treatment
regimen
control
group
bias
control
group
effect
ribavirin
could
distinguish
effect
therapi
corticosteroid
antivir
singlecentr
rct
sar
patient
compar
ribavirin
show
signific
differ
day
symptom
improv
discharg
four
present
evid
possibl
harm
includ
haemolyt
anaemia
liver
dysfunct
metabol
derang
synergi
ribavirin
ifn
discuss
section
ifn
similar
ribavirin
mycophenol
acid
inhibitor
cellular
inosin
monophosph
dehydrogenas
antivir
activ
number
virus
includ
influenza
via
mechan
mycophenol
acid
also
inhibit
purin
nucleotid
synthesi
lymphocyt
make
popular
immunosuppress
solidorgan
transplant
autoimmun
diseas
system
lupu
erythematosu
although
mycophenol
acid
vitro
murin
effect
sarscov
inhibit
merscov
concentr
achiev
standard
clinic
oral
dose
display
synergi
thiopurin
analogu
vitro
howev
common
marmoset
mycophenol
acidtr
anim
develop
sever
andor
fatal
diseas
higher
mean
viral
load
log
copiesglyceraldehyd
dehydrogenas
p
untreat
anim
mortal
rate
h
postinocul
mer
cov
untreat
mycophenol
acidtr
versu
lopinavirritonavirtr
use
mycophenol
acid
monotherapi
report
mer
ifnb
mycophenol
acid
combin
therapi
describ
retrospect
observ
studi
saudi
arabia
involv
patient
patient
receiv
ifnb
mycophenol
acid
surviv
howev
group
patient
lower
acut
physiolog
chronic
health
evalu
ii
apacheii
score
compar
rest
receiv
varieti
antivir
agent
includ
ribavirin
ifna
steroid
antibiot
cyclosporin
deriv
inhibit
cellular
peptidylprolyl
isomeras
activ
cyclophilin
import
replic
virus
includ
hiv
hepat
c
viru
nonimmunosuppress
cyclosporin
alisporivir
found
highli
potent
hepat
c
treatment
ic
inhibit
huh
cell
mgml
compar
cyclosporin
ic
mgml
also
found
combin
either
cyclosporin
result
addit
slightli
synergist
antivir
activ
vitro
activ
clinic
data
avail
efficaci
cyclosporin
sar
mer
cyclosporin
readili
avail
due
use
solidorgan
transplant
patient
therapi
autoimmun
condit
rheumatoid
arthriti
psoriasi
immun
suppress
effect
rais
concern
set
infect
especi
high
ec
c
max
ratio
standard
therapeut
dosag
chloroquin
antimalari
sequest
proton
lysosom
increas
intracellular
ph
chloroquin
inhibitori
vitro
multipl
virus
includ
influenza
dengu
viru
merscov
concentr
achiev
standard
clinic
oral
dose
howev
reduc
viral
replic
sarscov
infect
mice
possibl
cell
surfac
pathway
simultan
block
clinic
data
avail
efficaci
chloroquin
coronavirus
use
season
prophylaxi
influenza
studi
larg
rct
chloroquin
well
toler
fail
prevent
diseas
nitazoxanid
potent
type
ifn
induc
origin
develop
antiprotozo
agent
repurpos
broadspectrum
antivir
agent
undergo
develop
treatment
hepat
c
influenza
viral
respiratori
infect
addit
antivir
activ
nitazoxanid
inhibit
product
proinflammatori
cytokin
peripher
blood
mononuclear
cell
vitro
activ
nitazoxanid
possess
potent
antivir
activ
influenza
virus
one
top
three
inhibitor
demonstr
robust
anticoronaviru
activ
recent
screen
nih
clinic
collect
librari
shown
inhibit
mer
cov
cultur
cell
ic
mgml
similar
level
observ
influenza
virus
ic
achiev
human
follow
twice
daili
administr
nitazoxanid
extendedreleas
tablet
peak
trough
plasma
concentr
report
mgml
respect
clinic
data
efficaci
nitazoxanid
sar
mer
two
phase
rct
show
benefit
childhood
respiratori
infect
uncompl
influenza
adult
respect
antibiot
broadspectrum
antibiot
commonli
use
manag
mer
empir
treatment
sever
communityacquir
pneumonia
well
ventilatorassoci
bacteri
pneumonia
teicoplanin
glycopeptid
antibiot
inhibit
bacteri
cell
wall
synthesi
recent
found
action
merscov
ebola
viru
teicoplanin
found
potent
prevent
entri
merscov
sarscov
pseudotyp
virus
host
cellular
cytoplasm
furthermor
teicoplanin
inhibitori
effect
replicationcompet
viruslik
particl
low
ic
nm
teicoplanin
clinic
effect
treatment
gramposit
bacteri
infect
includ
enterococcu
faecali
staphylococc
aureu
streptococcu
viridan
pharmacodynam
studi
specif
merscov
requir
discern
antivir
efficaci
analog
mechan
mab
antivir
peptid
target
variou
region
protein
prevent
merscov
entri
host
cell
camostat
serin
proteas
inhibitor
good
safeti
profil
use
treat
chronic
pancreat
human
suppress
merscov
entri
human
bronchial
submucos
glandderiv
cell
viru
growth
howev
found
efficaci
merscov
infect
deriv
cell
immatur
lung
tissu
anoth
type
fusion
inhibitor
vitro
studi
heptad
repeat
peptid
synthes
peptid
deriv
domain
merscov
protein
specif
bind
domain
viral
protein
block
merscov
replic
proteinmedi
cell
cell
fusion
intranas
administr
effect
protect
adenoviru
dipeptidyl
peptidas
mice
infect
merscov
strain
without
mutat
region
protein
reduct
viral
titr
lung
protect
enhanc
combin
ifnb
combin
antivir
peptid
target
differ
region
subunit
protein
theoret
may
overcom
risk
drug
resist
investig
fusion
inhibitor
mer
remain
preclin
clinic
data
efficaci
fusion
inhibitor
sar
mer
vitro
activ
mannosebind
lectin
mbl
key
molecul
innat
immun
function
anteantibodi
specif
antibodi
respons
mbl
inhibit
viral
bind
via
sarscov
glycoprotein
retrospect
casecontrol
studi
serum
sar
patient
control
subject
show
higher
frequenc
haplotyp
associ
low
defici
level
mbl
sar
patient
control
subject
mbl
defici
therefor
possibl
suscept
factor
acquisit
sar
mbl
remain
investig
therapi
clinic
data
efficaci
mbl
sar
mer
corticosteroid
wide
use
sar
due
antiinflammatori
effect
cohort
treat
simultan
ribavirin
howev
potenti
local
system
immunosuppress
corticosteroid
concern
one
rct
conclud
administr
corticosteroid
might
enhanc
viral
replic
lung
shown
higher
plasma
sarscov
viral
load
slower
serum
viral
clearanc
week
ill
patient
given
hydrocortison
given
normal
salin
earli
phase
diseas
similar
find
corticosteroid
test
influenzaaffect
patient
retrospect
cohort
studi
show
use
corticosteroid
associ
increas
risk
prolong
lower
respiratori
tract
viral
replic
nosocomi
infect
ventilatorassoci
pneumonia
higher
mortal
mani
patient
sever
mer
treat
system
highdos
corticosteroid
intend
revers
progress
respiratori
distress
prevent
lung
fibrosi
proven
success
corticosteroid
improv
longerterm
outcom
ard
routin
use
recommend
addit
corticosteroid
also
associ
osteonecrosi
delirium
aspergillosi
discuss
challeng
select
appropri
pharmacolog
treatment
face
novel
infect
inconclus
data
drawn
mani
sourc
despit
discov
fairli
larg
number
repurpos
drug
activ
merscov
fulfil
potenti
clinic
set
agent
drawback
either
high
ec
c
max
ratio
clinic
dosag
immunosuppress
side
effect
discourag
clinic
trial
sporad
epidemiolog
also
made
patient
recruit
clinic
trial
difficult
use
therapeut
merscov
remain
investig
data
extrapol
use
sar
either
vitro
clinic
best
specul
valu
convalesc
plasma
ifn
without
ribavirin
lopinavir
ritonavir
like
benefici
evalu
retrospect
nonrandom
intervent
data
obtain
sar
outbreak
show
convalesc
plasma
brought
rapid
decreas
viraemia
reduc
mortal
treatment
convalesc
plasma
like
effect
signific
viraemia
henc
earli
administr
key
prospect
human
studi
investig
use
convalesc
plasma
mer
ongo
face
logist
recruit
challeng
plasma
product
immunoglobulin
vari
geograph
likewis
vari
efficaci
mer
given
small
number
mer
patient
signific
mortal
infect
may
suffici
convalesc
sera
scalabl
option
particularli
outsid
middl
east
crossreact
sarscov
merscov
antibodi
observ
unlik
use
therapeut
mab
could
offer
use
altern
rapidli
reproduc
far
shown
high
potenc
specif
howev
develop
like
temper
challeng
licens
fullscal
product
afford
cost
undefin
popul
ifn
ribavirin
without
lopinavirritonavir
report
therapi
mer
although
nonhuman
primat
studi
show
combin
treatment
ifn
ribavirin
andor
lopinavir
result
reduc
viru
replic
moder
host
respons
improv
clinic
outcom
five
smallscal
retrospect
studi
critic
ill
patient
fail
show
mortal
benefit
discrep
vitro
vivo
find
may
relat
high
ec
c
max
ratio
drug
delay
drug
administr
earli
drug
administr
essenti
mer
patient
rapid
progress
death
sar
patient
ribavirin
use
caution
vitro
studi
merscov
requir
high
serum
concentr
inhibit
dose
ribavirin
reduc
use
togeth
associ
multipl
side
effect
includ
haemolysi
electrolyt
imbal
liver
impair
occur
treat
patient
lopinavir
shown
limit
observ
studi
result
lower
mortal
less
progress
ard
sar
use
report
one
mer
patient
clear
viraemia
day
administr
lopinavirritonavir
ribavirin
suggest
antivir
administr
consid
soon
possibl
diagnosi
base
limit
clinic
evid
earlier
administr
ifn
ribavirin
result
trend
toward
improv
surviv
mer
similarli
sar
therapeut
benefit
observ
ribavirin
given
earlier
day
onset
symptom
corticosteroid
ribavirin
monotherapi
mycophenol
acid
like
caus
harm
benefit
corticosteroid
caus
local
system
immunosuppress
administr
associ
higher
plasma
viral
load
slower
viral
clearanc
higher
mortal
sar
furthermor
shown
improv
longerterm
outcom
ard
ribavirin
consid
use
monotherapi
due
poor
side
effect
profil
high
dosag
requir
inhibit
merscov
shown
effect
mer
sar
clinic
evid
ribavirin
deem
inconclus
clinic
data
efficaci
mycophenol
acid
sar
mer
howev
led
sever
andor
fatal
diseas
higher
mean
viral
load
anim
model
review
jac
anim
human
transmiss
mer
cov
continu
middl
east
like
infect
individu
continu
export
ill
countri
minim
experi
deal
understand
valu
risk
mani
treatment
option
need
urgent
select
therapeut
regimen
especi
necessarili
stress
public
period
host
countri
institut
medic
team
need
make
decis
base
bodi
avail
inform
give
anyth
clear
direct
treatment
need
appli
adher
research
treatment
protocol
systemat
data
collect
meanwhil
clinic
research
simpli
must
improv
abil
undertak
multicentr
multin
rct
outbreak
set
particularli
emerg
pathogen
none
declar
